Results 61 to 70 of about 22,802 (228)

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study. [PDF]

, 2017
ObjectiveParkinson's disease psychosis (PDP) is a frequent complication of idiopathic Parkinson's disease (iPD) with significant impact on quality of life and association with poorer outcomes.
Bizzarri, Cummings, Fernandez, Fernandez, Fénelon, Gama, Goldman, Hack, Hubbard, Kiferle, Lertxundi, McFarland, Meltzer, Meral, Mesquita, Mocci, Munhoz, Noel, Pagonabarraga, Prohorov, Rabey, Reichmann, Rolland, Seppi, Shotbolt, Starkstein, Thomas, Vanover, Weintraub, Zhu   +29 more
core   +2 more sources

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

The varieties of the psychedelic experience: A preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines [PDF]

, 2018
Classic psychedelics are substances of paramount cultural and neuroscientific importance. A distinctive feature of psychedelic drugs is the wide range of potential subjective effects they can elicit, known to be deeply influenced by the internal state of
Erowid, Earth, Erowid, Fire, Martínez Vivot, Rocío, Pallavicini, Carla, Sanz, Camila, Tagliazucchi, Enzo Rodolfo, Zamberlan, Federico   +6 more
core   +2 more sources

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor

eLife, 2018
Background: Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-HT) and dopamine receptors. Despite the therapeutic and scientific interest in LSD, specific receptor contributions to its neurobiological effects remain unknown ...
Katrin H Preller, Joshua B Burt, Jie Lisa Ji, Charles H Schleifer, Brendan D Adkinson, Philipp Stämpfli, Erich Seifritz, Grega Repovs, John H Krystal, John D Murray, Franz X Vollenweider, Alan Anticevic   +11 more
doaj   +1 more source

Functional brain imaging : a brief overview of imaging techniques and their use in human and canine anxiety research [PDF]

, 2011
When used in combination with specific radioactive markers, functional imaging modalities such as Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) enable the visualization of several neurotransmitter receptors and
Audenaert, Kurt, De Meester, Rudy, Dobbeleir, André, Peremans, Kathelijne, van Bree, Henri, Vandermeulen, Eva, Vermeire, Simon   +6 more
core  

Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response [PDF]

, 2011
Background: Selective serotonin reuptake inhibitors take several weeks to achieve their full antidepressant effects. Post-synaptic 5-HT_2A receptor activation is thought to be involved in this delayed therapeutic effect ...
A. F. Schatzberg, A. G. Wade, A. McConnachie, Blier, Buntinx, C. B. Nemeroff, Celada, Demyttenaere, E. Buntinx, G. M. Crawford, Gillespie, Guy, L. Haazen, Landen, T. Schlaepfer   +14 more
core   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Herbal highs: review on psychoactive effects and neuropharmacology [PDF]

, 2017
Background: A new trend among users of new psychoactive substances’ the consumption of “herbal highs”: plant parts containing psychoactive substances.
Graziano, S, Orsolini, L, Pichini, S., Rotolo, Mc, Schifano, F, Tittarelli, R   +5 more
core   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source